About: Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers
Creator	Hojo, Masayuki Izumi, Shinyu Sugiyama, Haruhito Takasaki, Jin Hayakawa, Kayoko Ohmagari, Norio Asai, Yusuke Mizokami, Masashi Sugiyama, Masaya Akiyama, Yutaro Fumihiko Hinoshita, ; Ide, ; Ishikane, Masahiro Kanda, Kohei Katagiri, Daisuke Kinoshita, Noriko Kustuna, ; Miyazato, Yusuke Morioka, Shinichiro Moriyama, Yuki Nakamoto, Takato Nakamura, Keiji Noiri, Eisei Nomoto, Hidetoshi Okuhama, Ayako Ota, ; Saito, Sho Suzuki, Tetsuya Terada, Junko Ujiie, ; Wakimoto, Yuji Yamamoto, ; Yanagawa, Yasuaki
Source	Medline; PMC
abstract	SUBJECTS: Early detection of coronavirus disease 2019 in patients likely to develop severe manifestations enables appropriate interventions, including rapid ICU admission. This study was conducted to determine whether noninvasive urine biomarkers can predict the clinical severity of coronavirus disease 2019. INTERVENTIONS: Not applicable. MEASUREMENTS AND MAIN RESULTS: This is single-center study, national center hospital designated for infectious disease. Fifty-eight patients who tested positive for severe acute respiratory syndrome coronavirus 2 in respiratory specimens through real-time reverse transcription-polymerase chain reaction were retrospectively studied. Urinary β2-microglobulin, liver-type fatty acid-binding protein were serially measured. Serum interferon-γ and monocyte chemotactic protein-1 were also evaluated. The 58 patients were assigned into three groups. Patients requiring intensive care were assigned to the severe group (n = 12). Patients treated with oxygen were assigned to the moderate group (n = 13). Other patients were assigned to the mild group (n = 33). Urine tests revealed that low β2-microglobulin and liver-type fatty acid-binding protein levels were associated with mild disease, whereas high levels were associated with severe disease. In severe cases, liver-type fatty acid-binding protein tended to be persistently high. The resulting cutoff values were β2-microglobulin; severe versus moderate + mild: 2,457 μg/dL (specificity 76.9% and sensitivity 90.0%, area under the receiver operating characteristic curve 85.9%), liver-type fatty acid-binding protein; severe versus moderate + mild: 22.0 μg/gCre (specificity 84.6% and sensitivity 90%, area under the receiver operating characteristic curve 91.8%). Urinary β2-microglobulin and serum interferon-γ/monocyte chemotactic protein-1 showed a similar trend. CONCLUSIONS: Evaluating urinary biomarkers such as β2-microglobulin and liver-type fatty acid-binding protein may allow determination of coronavirus disease 2019 patients with active cytokines and recognition of patients likely to become critically ill and requiring careful observation and early intervention.
has issue date	2020-07-31(xsd:dateTime)
bibo:doi	10.1097/cce.0000000000000170
bibo:pmid	32766565
has license	cc-by-nc-nd
sha1sum (hex)	8070a2183efaaf293126afab88c74cf82fbb4a5a
schema:url	https://doi.org/10.1097/cce.0000000000000170
resource representing a document's title	Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers
has PubMed Central identifier	PMC7402421
has PubMed identifier	32766565
schema:publication	Crit Care Explor
resource representing a document's body	covid:8070a2183efaaf293126afab88c74cf82fbb4a5a#body_text
is schema:about of	named entity 'tested' named entity 'serum' named entity 'rapid' named entity 'fatty acid-binding protein' named entity 'fatty acid-binding protein' named entity 'This' named entity 'urinary' named entity 'infectious disease' named entity 'β2-microglobulin' named entity 'moderate' named entity 'Urine' named entity 'CENTER' named entity 'NATIONAL' named entity 'CORONAVIRUS DISEASE 2019' named entity 'ADMISSION' named entity 'RECOGNITION' named entity 'GROUPS' named entity '90%' named entity 'MEASURED' named entity 'REAL-TIME' named entity 'HOSPITAL' named entity 'TREATED WITH' named entity 'INFECTIOUS DISEASE' named entity 'SUBJECTS' named entity 'EARLY INTERVENTION' named entity 'ASSOCIATED WITH' named entity 'LOW' named entity 'ICU' named entity 'CLINICAL' named entity 'RESULTING' named entity 'MODERATE' named entity 'APPROPRIATE' named entity 'EARLY DETECTION' named entity 'HIGH' named entity 'MILD DISEASE' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'BIOMARKERS' named entity 'detection' named entity 'curve' named entity 'critically ill' named entity 'cutoff' named entity 'interferon-γ' named entity 'manifestations' named entity 'patients' named entity 'mild' named entity 'determination' named entity 'chemotactic' named entity 'studied' named entity 'serially'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software